Have a personal or library account? Click to login
Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study Cover

Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study

Radiology and Oncology
Volume 57 (2023): Issue 3 (September 2023)
By: Mafei Kang,  Feng Xue,  Shengyuan Xu,  Jieqiong Shi and  Yunyan Mo  
Open Access
|Jul 2023

Authors

Mafei Kang

Department of Medical Oncology, Affiliated Hospital of Guilin Medical University, Guangxi Guilin, China

Feng Xue

Department of Medical Oncology, Affiliated Hospital of Guilin Medical University, Guangxi Guilin, China

Shengyuan Xu

Department of Medical Oncology, Affiliated Hospital of Guilin Medical University, Guangxi Guilin, China

Jieqiong Shi

Department of Medical Oncology, Affiliated Hospital of Guilin Medical University, Guangxi Guilin, China

Yunyan Mo

Moyunyan1001@163.com

Department of Medical Oncology, Affiliated Hospital of Guilin Medical University, Guangxi Guilin, China
DOI: https://doi.org/10.2478/raon-2023-0036 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 405 - 410
Submitted on: Feb 16, 2023
Accepted on: Jun 15, 2023
Published on: Jul 26, 2023
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
hepatocellular carcinoma (HCC),
anlotinib,
S-1,
molecule targeted therapy,
chemotherapy
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2023 Mafei Kang, Feng Xue, Shengyuan Xu, Jieqiong Shi, Yunyan Mo, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 57 (2023): Issue 3 (September 2023)